Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
53
GLPGF Quote, Financials, Valuation and Earnings
Last price:
$33.27
Seasonality move
:
9.04%
Day range:
$33.27 - $33.27
52-week range:
$22.39 - $34.00
Dividend yield:
0%
P/E ratio:
5.58x
P/S ratio:
1.71x
P/B ratio:
0.58x
Volume:
--
Avg. volume:
1
1-year change:
44.58%
Market cap:
$2.2B
Revenue:
$1.3B
EPS (TTM):
$5.96
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
$28.6M | -- | -63.73% | -- | -- |
|
ARSUF
Fagron NV
|
-- | -- | -- | -- | -- |
|
CLYYF
Celyad Oncology SA
|
-- | -- | -- | -- | -- |
|
UCBJY
UCB SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
$33.27 | -- | $2.2B | 5.58x | $0.00 | 0% | 1.71x |
|
ARSUF
Fagron NV
|
$27.00 | -- | $2B | 19.22x | $0.39 | 1.21% | 1.84x |
|
CLYYF
Celyad Oncology SA
|
$0.35 | -- | $15.7M | -- | $0.00 | 0% | 617.02x |
|
UCBJY
UCB SA
|
$153.08 | -- | $57.4B | 32.91x | $0.79 | 0.52% | 6.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
0.21% | 1.320 | 0.39% | 19.68x |
|
ARSUF
Fagron NV
|
40.95% | 0.807 | -- | 0.88x |
|
CLYYF
Celyad Oncology SA
|
-- | -10.136 | -- | -- |
|
UCBJY
UCB SA
|
21.7% | 0.549 | -- | 1.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GLPGF
Galapagos NV
|
$1B | $871.1M | 12.39% | 12.43% | 83.08% | -$50.4M |
|
ARSUF
Fagron NV
|
-- | -- | 10.32% | 17.38% | -- | -- |
|
CLYYF
Celyad Oncology SA
|
-- | -- | -- | -- | -- | -- |
|
UCBJY
UCB SA
|
-- | -- | 10.75% | 13.88% | -- | -- |
Galapagos NV vs. Competitors
-
Which has Higher Returns GLPGF or ARSUF?
Fagron NV has a net margin of 86.86% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of 12.43% beat Fagron NV's return on equity of 17.38%.
Company Gross Margin Earnings Per Share Invested Capital GLPGFGalapagos NV99.95% $13.81 $3.8B ARSUFFagron NV-- -- $1B -
What do Analysts Say About GLPGF or ARSUF?
Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Fagron NV has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than Fagron NV, analysts believe Galapagos NV is more attractive than Fagron NV.
Company Buy Ratings Hold Ratings Sell Ratings GLPGFGalapagos NV0 0 0 ARSUFFagron NV0 0 0 -
Is GLPGF or ARSUF More Risky?
Galapagos NV has a beta of 0.489, which suggesting that the stock is 51.115% less volatile than S&P 500. In comparison Fagron NV has a beta of -0.009, suggesting its less volatile than the S&P 500 by 100.909%.
-
Which is a Better Dividend Stock GLPGF or ARSUF?
Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fagron NV offers a yield of 1.21% to investors and pays a quarterly dividend of $0.39 per share. Galapagos NV pays -- of its earnings as a dividend. Fagron NV pays out 22.48% of its earnings as a dividend. Fagron NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GLPGF or ARSUF?
Galapagos NV quarterly revenues are $1B, which are larger than Fagron NV quarterly revenues of --. Galapagos NV's net income of $910.8M is higher than Fagron NV's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 5.58x while Fagron NV's PE ratio is 19.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 1.71x versus 1.84x for Fagron NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLPGFGalapagos NV1.71x 5.58x $1B $910.8M ARSUFFagron NV1.84x 19.22x -- --
-
Which has Higher Returns GLPGF or CLYYF?
Celyad Oncology SA has a net margin of 86.86% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of 12.43% beat Celyad Oncology SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GLPGFGalapagos NV99.95% $13.81 $3.8B CLYYFCelyad Oncology SA-- -- -- -
What do Analysts Say About GLPGF or CLYYF?
Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Celyad Oncology SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than Celyad Oncology SA, analysts believe Galapagos NV is more attractive than Celyad Oncology SA.
Company Buy Ratings Hold Ratings Sell Ratings GLPGFGalapagos NV0 0 0 CLYYFCelyad Oncology SA0 0 0 -
Is GLPGF or CLYYF More Risky?
Galapagos NV has a beta of 0.489, which suggesting that the stock is 51.115% less volatile than S&P 500. In comparison Celyad Oncology SA has a beta of -0.531, suggesting its less volatile than the S&P 500 by 153.066%.
-
Which is a Better Dividend Stock GLPGF or CLYYF?
Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celyad Oncology SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Celyad Oncology SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLPGF or CLYYF?
Galapagos NV quarterly revenues are $1B, which are larger than Celyad Oncology SA quarterly revenues of --. Galapagos NV's net income of $910.8M is higher than Celyad Oncology SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 5.58x while Celyad Oncology SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 1.71x versus 617.02x for Celyad Oncology SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLPGFGalapagos NV1.71x 5.58x $1B $910.8M CLYYFCelyad Oncology SA617.02x -- -- --
-
Which has Higher Returns GLPGF or UCBJY?
UCB SA has a net margin of 86.86% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of 12.43% beat UCB SA's return on equity of 13.88%.
Company Gross Margin Earnings Per Share Invested Capital GLPGFGalapagos NV99.95% $13.81 $3.8B UCBJYUCB SA-- -- $14.5B -
What do Analysts Say About GLPGF or UCBJY?
Galapagos NV has a consensus price target of --, signalling downside risk potential of --. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than UCB SA, analysts believe Galapagos NV is more attractive than UCB SA.
Company Buy Ratings Hold Ratings Sell Ratings GLPGFGalapagos NV0 0 0 UCBJYUCB SA0 0 0 -
Is GLPGF or UCBJY More Risky?
Galapagos NV has a beta of 0.489, which suggesting that the stock is 51.115% less volatile than S&P 500. In comparison UCB SA has a beta of 0.705, suggesting its less volatile than the S&P 500 by 29.543%.
-
Which is a Better Dividend Stock GLPGF or UCBJY?
Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.52% to investors and pays a quarterly dividend of $0.79 per share. Galapagos NV pays -- of its earnings as a dividend. UCB SA pays out 15.96% of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GLPGF or UCBJY?
Galapagos NV quarterly revenues are $1B, which are larger than UCB SA quarterly revenues of --. Galapagos NV's net income of $910.8M is higher than UCB SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 5.58x while UCB SA's PE ratio is 32.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 1.71x versus 6.69x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLPGFGalapagos NV1.71x 5.58x $1B $910.8M UCBJYUCB SA6.69x 32.91x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
